Navigation Links
MonoSol Rx Granted US Patent for Thin Film Manufacturing Process
Date:4/15/2008

- Validates MonoSol Rx as Leading Innovator in Medicated Thin Film

Technology -

WARREN, N.J., April 15 /PRNewswire/ -- MonoSol Rx, a drug delivery company specializing in quick dissolving thin film pharmaceutical products, today announced that it has been granted U.S. patent No. 7,357,891 from the United States Patent and Trademark Office (USPTO). The patent, which is expected to issue on April 15, 2008, relates to the Company's proprietary mixing system technology and controlled film drying process.

"Granting of this patent is a significant milestone for MonoSol Rx as it validates and protects our thin film drug delivery technology. As we strive to expand the patent protection of our thin film technology, this milestone serves to fortify our leadership position in the delivery of prescription drugs using thin film" said A. Mark Schobel, president and chief executive officer of MonoSol Rx. "Our proprietary mixing and drying processes enable us to maintain precise content uniformity of the drug, incorporate taste-masked drug encapsulations, and allow the manufacture of sensitive drug targets that may otherwise not be possible. Each of these factors, combined with the convenience and dosing benefits of thin film, are key to the success of our technology, and help to differentiate MonoSol Rx from similar thin film offerings and other modes of drug delivery."

The patent relates to MonoSol Rx's Dual Integrated Mixing System. This patented mixing process is designed to provide a continuous batch coating of a drug contained in the film to ensure product uniformity while delivering consistent organoleptic performance throughout the film manufacturing process.

Also encompassed in the patent is MonoSol Rx's controlled film drying process. This controlled drying process is critical to maintaining content uniformity of a drug within the film thereby ensuring accurate and predictable dosing for patients.

Mr. Schobel also said, "This is an important acknowledgement of the innovative technology that MonoSol Rx has developed for thin film drug delivery. We are committed to pursuing and developing technology that provides significant advantages for MonoSol Rx and its development partners."

About MonoSol Rx

MonoSol Rx is a drug delivery company specializing in proprietary, dissolving thin film pharmaceutical products. The Company's thin film technology, which is similar in size, shape and thickness to a postage stamp, dissolves rapidly and utilizes a novel process and proprietary encapsulation compositions to mask the taste of the drug contained within the film. MonoSol Rx's strategy is to develop and partner innovative thin film strip products in the prescription, generic and OTC pharmaceutical markets and to establish a leadership position in thin film drug delivery technology through continued development of its drug delivery technology and intellectual property portfolio.

Contacts:

Jason Rando/Elizabeth Scott

The Ruth Group

646.536.7025/7014

jrando@theruthgroup.com

escott@theruthgroup.com


'/>"/>
SOURCE MonoSol Rx
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
2. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
3. USC granted $8.4 million for autism research
4. Aida Granted Additional Anti-Cancer Patent
5. CME LLC Granted Five-Year Full Approval by the American Psychological Association
6. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
7. TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
8. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
9. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
10. Phylonix granted broad European patent for transplanting human cells into zebrafish
11. Seven Community Service Organizations Granted Over $60,000 From Delta Dental Of Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is proud to sponsor ... event brings together top non-profit leaders, ultimate organizations, and coaches from around the US. ... Bay Area Disc Program Director of Youth and Education, describes this year YUCC as ...
(Date:2/6/2016)... St. Petersburg, FL (PRWEB) , ... February 06, 2016 , ... ... AsSeenOnTV.pro are pleased to announce the launch of a new DRTV campaign with Belly ... rug. If having tried everything from sprays to puppy pads and find nothing works, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran ... it started in 2003. This year, he ran all 26.2 miles with a green ... team the Miami Heat. , This Sunday, while many are watching the Superbowl, Steven ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... the company's lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability ... in design and manufacturing not only reduce the weight of the unit, they ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... stage for new clinical and scientific initiatives have all marked the last 12 ... appointed President and CEO of the nation’s oldest cancer center, Candace S. Johnson, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical Ltd. ... device company, announced today that William Griffing ... America, is scheduled to participate in the Leerink ... on February 11, 2016 in New ... institutional investors to meet with the Mr. Griffing ...
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") ... POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following ... shareholders of Tribute. The combined company will operate under ... with operations in Canada , ... States . Under the terms of the Agreement ...
(Date:2/5/2016)... 2016 --> ... that the global active pharmaceuticals ingredients (APIs) market stood ... reach US$185.9 bn by 2020. It is expected to ... 2020. The title of the report is "Active Pharmaceutical ... and by Therapeutic Area) - Global Industry Analysis, Size, ...
Breaking Medicine Technology: